FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for PROLIA (denosumab) submitted by Amgen, Inc., resulting in updated labeling for osteoporosis indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Osteoporosis
• Osteoporosis
• Osteoporosis in Men
• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

SUPPL AP for PROLIA (DENOSUMAB)